Sort
30,917 grants matching “tumor microenvironment”
Mechanisms of resistance to treatment in aggressive prostate cancers
$577,402Adam Sowalsky · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
A framework for integrating MR imaging and clinical tests for prediction of outcomes in multiple myeloma treatment
$577,373Chuan Zhou · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Temporal analysis of the GBM tumor microenvironment during myeloid cell activating therapy
$577,345Ralph Weissleder · Massachusetts General Hospital · R01 · FY2023 · CA
Research Test-Bed Unit
$577,203Daniela E Matei · Northwestern University · U54 · FY2022 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
$577,137Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2019 · CA
(PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
$577,096David B Agus · University Of Southern California · R01 · FY2015 · CA
Reprogramming PDAC tumor microenvironment to improve immunotherapy
$577,095Rakesh K. Jain · Massachusetts General Hospital · U01 · FY2021 · CA
Reprogramming PDAC tumor microenvironment to improve immunotherapy
$577,095Rakesh K. Jain · Massachusetts General Hospital · U01 · FY2020 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
$577,069David P Carbone · Ohio State University · R01 · FY2021 · CA
A Mechanoimmunological Basis for Metastatic Site Preference
$577,034Morgan A Huse · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment
$577,033Alexander V Ljubimov · Cedars-Sinai Medical Center · R01 · FY2023 · CA
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer
$576,966Yoon Yeo · Purdue University · R01 · FY2023 · CA
Single-cell characterization of tumor and microenvironment co-evolution in Peripheral T-cell Lymphomas
$576,903Raul Rabadan · Columbia University Health Sciences · U01 · FY2023 · CA
A Portable low-cost, Point of Investigation CapCell Scope to Image and Quantify the Major Axes of Metabolism and the Associated Vasculature in In vitro and In vivo Biological Models
$576,841Nimmi Ramanujam · Duke University · R01 · FY2020 · EB
Project 2: Local immunotherapy corrects chemokine patterns in ovarian cancer
$576,791Robert Page Edwards · Roswell Park Cancer Institute Corp · P01 · FY2023 · CA
The identification of human hepatocellular carcinoma metastasis genes
$576,759Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
UW PET/CT Acquisition
$576,756Jamey P Weichert · University Of Wisconsin-Madison · S10 · FY2024 · OD
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer
$576,726Yoon Yeo · Purdue University · R01 · FY2022 · CA
Senescent CAFs in Breast Cancer Progression
$576,723Sheila A Stewart · Washington University · R01 · FY2025 · AG
Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma
$576,703Ann M Moormann · Univ Of Massachusetts Med Sch Worcester · R01 · FY2016 · CA
Tumor and Host Immune signatures associated with health disparities in outcomes following GD2 immunotherapy in neuroblastoma
$576,659Kelly C Goldsmith · Emory University · R01 · FY2024 · CA
MGH- PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
$576,657Andrew T Chan · Massachusetts General Hospital · OT2 · FY2024 · CA
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer
$576,611Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2021 · CA
Protein kinase C signaling in prostate cancer health disparities
$576,595Marcelo Gabriel Kazanietz · University Of Miami School Of Medicine · R01 · FY2024 · CA
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors
$576,552Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2018 · CA